Welcome
Support Centre
21 March 2013 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
International collaborative ovarian neoplasm studies (2): a trial of cap versus carboplatin in advanced ovarian cancer
ISRCTN ISRCTN48215558
DOI 10.1186/ISRCTN48215558
ClinicalTrials.gov identifier
EudraCT number
Public title International collaborative ovarian neoplasm studies (2): a trial of cap versus carboplatin in advanced ovarian cancer
Scientific title
Acronym N/A
Serial number at source ICON2
Study hypothesis To compare cyclophosphamide, doxorubicin and cisplatin (CAP) with single agent carboplatin in patients with advanced ovarian cancer.
Lay summary
Ethics approval Not provided at time of registration.
Study design Randomised controlled trial
Countries of recruitment International
Disease/condition/study domain Ovarian cancer
Participants - inclusion criteria 1. Chemotherapy indicated
2. No previous malignancy
3. No prior radiotherapy or chemotherapy
4. No contraindication to chemotherapy
Participants - exclusion criteria Does not meet inclusion criteria
Anticipated start date 01/01/1991
Anticipated end date 31/12/1996
Status of trial Completed
Patient information material
Target number of participants 2000 in 9 countries
Interventions 1. Cyclophosphamide, doxorubicin and cisplatin (CAP)
2. Single agent carboplatin
Primary outcome measure(s) Survival time, progression-free survival
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Medical Research Council (MRC) (UK)
Trial website
Publications 2009 results in http://www.ncbi.nlm.nih.gov/pubmed/9843101
Contact name Ms  Claire  Amos
  Address MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Email
Sponsor Medical Research Council (MRC) (UK)
  Address 20 Park Crescent
  City/town London
  Zip/Postcode W1B 1AL
  Country United Kingdom
  Tel +44 (0)20 7636 5422
  Fax +44 (0)20 7436 6179
  Email clinical.trial@headoffice.mrc.ac.uk
  Sponsor website: http://www.mrc.ac.uk
Date applied 28/02/2001
Last edited 02/07/2009
Date ISRCTN assigned 28/02/2001
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2013 ISRCTN unless otherwise stated.